SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 269-275

  Zhang, Peng ^a   Jiang, Guanmin ^a   Gao, Jiao ^b   Li, Lingling ^a   Du, Jun ^a   Jiao, Xingyuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gallbladder carcinoma; IFN; Indoleamine 2,3 dioxygenase; JAK STAT1; SAHA; Tumor immune tolerance

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 1; JANUS KINASE; STAT1 PROTEIN; VORINOSTAT;

ARTICLE; CARCINOMA CELL; CELL NUCLEUS; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GALLBLADDER CARCINOMA; GAMMA ACTIVATION SITE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERFERON STUMULATED RESPONSE ELEMENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXAMIC ACIDS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; JANUS KINASES; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84872844243     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2073     Document Type: Article

References (32)

1. Jiao XY, Ren JL, Chen HY, et al: Ala499Val (C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with the risk of primary gallbladder adenocarcinoma: a case-control study in China. Carcinogenesis 32: 496-501, 2011.
2. Jiao XY, Huang JF, Wu SL, et al: HOGG1 Ser326Cys polymorphism and susceptibility to gallbladder cancer in a Chinese population. Int J Cancer 121: 501-505, 2007.
3. Reid KM, Ramos-De la Medina A and Donohue JH: Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 11: 671-681, 2007.
4. Munn DH and Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154, 2007.
5. Takikawa O: Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochem Biophys Res Commun 338: 12-19, 2005.
6. Soliman H, Mediavilla-Varela M and Antonia S: Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J 16: 354-359, 2010.
7. Karanikas V, Zamanakou M, Kerenidi T, et al: Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6: 1258-1262, 2007.
8. Pine R: Convergence of TNFalpha and IFNgamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element. Nucleic Acids Res 25: 4346-4354, 1997.
9. Yoshida N, Ino K, Ishida Y, et al: Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14: 7251-7259, 2008.
10. Liu P, Xie BL, Cai SH, et al: Expression of indoleamine 2,3-di-oxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes. BMC Cancer 9: 416, 2009.
11. Miyazaki T, Moritake K, Yamada K, et al: Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation. J Neurosurg 111: 230-237, 2009.
12. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E and Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319, 2005.
13. Zeng J, Cai S, Yi Y, et al: Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan. Cancer Res 69: 3963-3970, 2009.
14. Zhang KS, Li GC, He YW, et al: Curcumin inhibiting the expression of indoleamine 2,3-dioxygenase induced by IFN-? in cancer cells. Zhong Yao Cai 31: 1207-1211, 2008 (In Chinese).
15. Platanias LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev 5: 375-386, 2005.
16. Klampfer L, Huang J, Sasazuki T, Shirasawa S and Augenlicht L: Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res 1: 855-862, 2003.
17. Chon SY, Hassanain HH, Pine R and Gupta SL: Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J Interferon Cytokine Res 15: 517-526, 1995.
18. Yamaguchi H, Chen CT, Chou CK, et al: Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene 29: 5619-5629, 2010.
19. Sun PC, Tzao C, Chen BH, Liu CW, Yu CP and Jin JS: Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci 17: 76, 2010.
20. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
21. Vigushin DM and Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1-13, 2002.
22. Frew AJ, Johnstone RW and Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280: 125-133, 2009.
23. Zong H, Yin B, Chen J, Ma B, Cai D and He X: Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med 217: 203-208, 2009.
24. Qing Y and Stark GR: Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 279: 41679-41685, 2004.
25. Kobayashi N, Kubota K, Kato S, et al: FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 10: 631-640, 2010.
26. Munn DH: Indoleamine 2,3-dioxygenase, tumor induced tolerance and counter regulation. Curr Opin Immunol 18: 220-225, 2006.
27. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S and Ishiguro N: Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 26: 1005-1012, 2009.
28. Dai W and Gupta SL: Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem 265: 19871-19877, 1990.
29. Kadoya A, Tone S, Maeda H, Minatogawa Y and Kido R: Gene structure of human indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 189: 530-536, 1992.
30. Konan KV and Taylor MW: Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 271: 19140-19145, 1996.
31. Boehm U, Klamp T, Groot M and Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol 15: 749-795, 1997.
32. Jeong YI, Kim SW, Jung ID, et al: Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem 284: 3700-3708, 2009.